Análisis opcionales del producto
Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Sanofi's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $104.3B | |
|---|---|---|
| P/E (forward) | 8.4x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $40.56B | $41.62B | $44.29B | $46.72B | +4.8% |
| Gross profit | $28.68B | $28.99B | $31.08B | $33.67B | +5.5% |
| Operating income | $10.40B | $6.89B | $7.40B | $6.80B | -13.2% |
| Net income | $8.37B | $5.40B | $5.56B | $7.81B | -2.3% |
| EPS (diluted) | $2.69 | $2.16 | $2.30 | $3.20 | +6.0% |
| EBITDA | $13.51B | $11.32B | $10.99B | $12.48B | -2.6% |
| R&D | $6.50B | $6.51B | $7.39B | $7.84B | +6.5% |
| SG&A | $8.74B | $9.48B | $9.82B | $10.24B | +5.4% |
Recent company headlines from major financial publishers.
Revenue accelerates beyond the historical 4.82% CAGR toward the 6.12% next-year estimate, driven by successful pipeline commercialization. Operating margins improve past 20%, and the equity partially re-rates toward the peer median.
Growth remains stable, anchored by vaccines and rare diseases. The 12.0x terminal multiple reflects a conservative partial re-rating from the current 8.4x, deliberately constrained below peers due to the rigid 97.7% dividend payout policy.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 6.3% | $61.9 | $69.2 | $78.4 | $89.5 | $89.5 |
| 7.3% | $51.2 | $56.0 | $61.9 | $69.2 | $78.4 |
| 8.3% | $43.6 | $47.1 | $51.2 | $56.0 | $61.9 |
| 9.3% | $38.0 | $40.6 | $43.6 | $47.1 | $51.2 |
| 10.3% | $33.6 | $35.7 | $38.0 | $40.6 | $43.6 |
Upcoming earnings date and setup when available.
La calificación que llevaba la edición de análisis publicada cada mes. Una calificación compara el precio en la fecha del análisis con el valor razonable; no es un registro de si la valoración acertó.
| Año | ene | feb | mar | abr | may | jun | jul | ago | sept | oct | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
